US20190133952A1 - Preparation method of sustained-release microparticles - Google Patents

Preparation method of sustained-release microparticles Download PDF

Info

Publication number
US20190133952A1
US20190133952A1 US16/095,315 US201716095315A US2019133952A1 US 20190133952 A1 US20190133952 A1 US 20190133952A1 US 201716095315 A US201716095315 A US 201716095315A US 2019133952 A1 US2019133952 A1 US 2019133952A1
Authority
US
United States
Prior art keywords
microparticles
water
sustained
preparation
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US16/095,315
Other languages
English (en)
Inventor
Feng Liu
Shuting LAI
Yang Zheng
Fuchun CAO
Yuanfa LIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AC Pharmaceuticals Co Ltd
Original Assignee
AC Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AC Pharmaceuticals Co Ltd filed Critical AC Pharmaceuticals Co Ltd
Assigned to AC PHARMACEUTICALS CO., LTD. reassignment AC PHARMACEUTICALS CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CAO, Fuchun, LAI, Shuting, LIAN, Yuanfa, LIU, FENG, ZHENG, YANG
Publication of US20190133952A1 publication Critical patent/US20190133952A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35Corticotropin [ACTH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Definitions

  • the solvent removal in step 4) may use the following method:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
US16/095,315 2016-04-26 2017-04-24 Preparation method of sustained-release microparticles Pending US20190133952A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610269834.1A CN105963258B (zh) 2016-04-26 2016-04-26 一种缓释微粒的制备方法
CN201610269834.1 2016-04-26
PCT/CN2017/081640 WO2017186077A1 (zh) 2016-04-26 2017-04-24 一种缓释微粒的制备方法

Publications (1)

Publication Number Publication Date
US20190133952A1 true US20190133952A1 (en) 2019-05-09

Family

ID=56994077

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/095,315 Pending US20190133952A1 (en) 2016-04-26 2017-04-24 Preparation method of sustained-release microparticles

Country Status (4)

Country Link
US (1) US20190133952A1 (de)
EP (1) EP3434263B1 (de)
CN (1) CN105963258B (de)
WO (1) WO2017186077A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105963258B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
US11612563B2 (en) 2017-07-17 2023-03-28 Medincell Pharmaceutical composition
US20210154147A1 (en) * 2018-10-19 2021-05-27 Ac Pharmaceuticals Co., Ltd. Preparation method of sustained-release microparticles
CN110498919B (zh) * 2019-07-26 2022-03-01 河南师范大学 一种酯化度可控的γ-PGA-Bn的合成方法
CN111150883A (zh) * 2020-01-14 2020-05-15 北京四环制药有限公司 可生物降解的注射填充物及其制备方法和其应用
KR20220032301A (ko) * 2020-09-07 2022-03-15 (주)인벤티지랩 약물의 지속 방출을 위한 서방형 마이크로입자
CN112354010A (zh) * 2020-11-27 2021-02-12 曲阜师范大学 一种聚γ-谷氨酸/壳聚糖/柠檬酸钙生物材料及其制备方法
CN112603892B (zh) * 2020-12-18 2023-09-05 中国药科大学 一种载药微球及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556642A (en) * 1992-07-16 1996-09-17 Tanabe Seiyaku Co., Ltd. Method for producing sustained release microsphere preparation
US6235224B1 (en) * 1995-07-21 2001-05-22 Brown University Research Foundation Process for preparing microparticles through phase inversion phenomena
US20020198315A1 (en) * 1992-05-28 2002-12-26 Hutchinson Francis Gowland Salts of peptides with carboxy-terminated polyesters
US20080131513A1 (en) * 2004-04-30 2008-06-05 Byung Ho Woo Sustained-Release Microspheres and Methods of Making and Using Same
US20100316571A1 (en) * 2007-10-27 2010-12-16 The Trustees Of The University Of Pennsylvania Method and Compositions for Polymer Nanocarriers Containing Therapeutic Molecules

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3738228A1 (de) * 1987-11-11 1989-05-24 Hoechst Ag Verfahren zur herstellung von bioabbaubaren mikrokapseln wasserloeslicher peptide und proteine sowie nach diesem verfahren erhaltene mikrokapseln
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
JP3191004B2 (ja) 1995-12-15 2001-07-23 武田薬品工業株式会社 マイクロスフェアの製造法
AR012448A1 (es) 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US6270700B1 (en) 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides
WO2001083594A1 (fr) * 2000-04-28 2001-11-08 Tanabe Seiyaku Co., Ltd. Procede de preparation d'une microsphere
US20050064039A1 (en) * 2001-12-26 2005-03-24 Tomomichi Futo Novel microsphere and method for production thereof
MXPA06000720A (es) 2003-07-18 2006-08-23 Baxter Int Metodos para fabricacion, usos y composiciones de particulas esfericas pequenas preparadas por separacion de fase controlada.
AR074603A1 (es) 2008-12-15 2011-01-26 Novartis Ag Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit
CN101721375B (zh) 2009-12-30 2012-05-30 上海交通大学 胰岛素缓释微米球组合物及其制备方法
CN102233129B (zh) * 2010-04-29 2014-07-09 上海交通大学 一种预防或治疗视网膜损伤的长效缓释制剂及其制备方法
US20140128431A1 (en) * 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
CN102885785B (zh) 2012-09-26 2014-01-15 复旦大学附属金山医院 含阿霉素纳米药物微球及其制备方法
CN102871969A (zh) 2012-09-28 2013-01-16 上海交通大学医学院附属新华医院 促红细胞生成素微球在制备治帕金森病运动并发症药物中的应用
CN105168137A (zh) * 2014-06-23 2015-12-23 天津金耀集团有限公司 一种乳糖塞来昔布药物组合物
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
US20160083345A1 (en) * 2014-09-19 2016-03-24 Cadila Healthcare Limited Polymorphic forms of lomitapide and its salts and processes for their preparation
CN105963258B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020198315A1 (en) * 1992-05-28 2002-12-26 Hutchinson Francis Gowland Salts of peptides with carboxy-terminated polyesters
US5556642A (en) * 1992-07-16 1996-09-17 Tanabe Seiyaku Co., Ltd. Method for producing sustained release microsphere preparation
US6235224B1 (en) * 1995-07-21 2001-05-22 Brown University Research Foundation Process for preparing microparticles through phase inversion phenomena
US20080131513A1 (en) * 2004-04-30 2008-06-05 Byung Ho Woo Sustained-Release Microspheres and Methods of Making and Using Same
US20100316571A1 (en) * 2007-10-27 2010-12-16 The Trustees Of The University Of Pennsylvania Method and Compositions for Polymer Nanocarriers Containing Therapeutic Molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Berkland, Journal of Controlled Release, 82, 2002 (Year: 2002) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof

Also Published As

Publication number Publication date
EP3434263A1 (de) 2019-01-30
EP3434263A4 (de) 2019-03-27
CN105963258B (zh) 2021-01-22
EP3434263B1 (de) 2020-07-15
WO2017186077A1 (zh) 2017-11-02
CN105963258A (zh) 2016-09-28

Similar Documents

Publication Publication Date Title
EP3434263B1 (de) Verfahren zur herstellung eines mikropartikels mit verzögerter freisetzung
EP3434262B1 (de) Verfahren zur herstellung von mikrogranulat mit verzögerter freisetzung
US10646572B2 (en) Pharmaceutical compositions with enhanced stability
CN105878191B (zh) 缓释微粒的制备方法、制得的缓释微粒及其应用
RU2422134C1 (ru) Композиция биоразлагающихся микросфер, пригодная для контролируемого высвобождения контролирующего уровень глюкозы пептида, и ее состав
AU2003217367B2 (en) Polymer-based compositions for sustained release
WO2017186074A1 (zh) 缓释微粒的制备方法、制得的缓释微粒及其应用
US20220133630A1 (en) Preparation method of sustained-release microparticles
BRPI0715469A2 (pt) composiÇÕes farmacÊuticas para a liberaÇço sustentada de peptÍdeos
WO2002053136A1 (fr) Preparations a liberation soutenue
US20210154147A1 (en) Preparation method of sustained-release microparticles
WO2017186076A1 (zh) 一种固体分散体及其制备方法与应用
WO2004073749A1 (ja) 徐放性製剤用の分散剤
JP4683319B2 (ja) 徐放性製剤用の分散剤

Legal Events

Date Code Title Description
AS Assignment

Owner name: AC PHARMACEUTICALS CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIU, FENG;LAI, SHUTING;ZHENG, YANG;AND OTHERS;REEL/FRAME:047239/0523

Effective date: 20181018

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION COUNTED, NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED